Oncology

29 Aug 2017

1264
(34 votes)

Rigvir® Virus in Latvia: Case Evaluation In 48-72 Hours At The World’s Only Virotherapy Cancer Clinic

If you’ve been cancer clean after chemo, radio, or surgery, but then the disease returned, most likely you are searching for alternative treatment. And while there are a few countries offering virotherapy along with vitamin C injections and hyperthermia, here’s why it can be a good idea to consider Latvia in the first place.

  • Rigvir® has initially been developed in Latvia. 
  • The Chief Oncologist of Latvia is a board member.  
  • Latvia offers inpatient and outpatient virotherapy. 
  • Latvia is a teaching hub.

Rigvir® has initially been developed in Latvia. This means whether or not you qualify for Rigvir®, you will receive a clear “yes” or “no” from the medical team of local oncologists and immunologists backed by their experience since 1960’s.

The Chief Oncologist of Latvia is a board member. She decides whether a cross-border patient like you can benefit from Rigvir® therapy. This doesn’t mean she will necessarily evaluate your case. But you can rest assured that your medical files will get an expert look from Rigvir® specialists you won’t find elsewhere.

Latvia offers both inpatient and outpatient virotherapy. This means you can either fly to Latvia or stay home and carry on with your everyday life while receiving the virotherapy in the background. (More about it below).

Latvia is a teaching hub. Cancer specialists from other parts of the world complete virotherapy training in Latvia. This means that if complicated patient cases arise, the virotherapists in Latvia are the ones who can significantly contribute to the debate.

rigvir cancer

Rigvir® vial contains ECHO-7 virus to fight tumors

Your Pathology Report, Complete Blood Count, and Other Three Medical Files You Need To Collect To Qualify For Rigvir® Therapy

Before we take a deep dive into each virotherapy package offered by virotherapists in Latvia, let’s run through the list of medical files you need to gather for the oncologists to evaluate your case.

 

These records are necessary for the medical team to study your case. Once you submit the required medical files, you will have the medical statement specifying whether or not you qualify for Rigvir® sent to your email. Normally the evaluation process takes not more than 48-72 hours.

Our experience shows that the U.S. patients manage to provide the papers faster than those living in Europe. In either case, it wouldn’t hurt to start collecting your medical records as soon as possible regardless of your geography.

If You Qualify For Rigvir® Therapy You May Get Your Treatment In Latvia from 7,000 Euros Or At Home from 3,100 Euros

If you qualify as a suitable candidate for virotherapy, you have two options: travel to Latvia and start your Rigvir® therapy under the daily supervision of the medical team or receive your treatment at home. 

Option 1. Flying to Latvia: 7 days in Latvia PLUS 3-month follow-up plan at home supervised by the world’s most experienced virotherapists from 7,000 Euros.

If you are able to travel to Latvia, it’s always best to start with a 7-day Complex Start-Up Virotherapy Package for 7,000 Euros (roughly 8,250.00 USD, 6,210.00 GBP, 10,325.00 CAD, 10,490.00 AUD). This way the oncologists will see how well your body responses to Rigvir® and immediately introduce appropriate changes in your treatment plan if needed.

Once you complete the virotherapy course, you’ll receive a 3-month follow-up treatment plan with the recommended number of Rigvir® vials (they are charged separately). Based on your blood tests performed during the 3-month period, your oncologist in Latvia will decide whether you will benefit from continuing your Rigvir® therapy. If so, you will be prescribed further treatment.

 

Option 2. Staying home: 3-month home-based treatment supervised by the world’s most experienced virotherapists and your local oncologist from 3,100 Euros.

So, if you aren’t able to travel over to Latvia, Remote Start-Up Virotherapy Package can be something to consider. Importantly, the package is offered in rare cases when the flight may pose threat to your health or there are other risks which become obvious during your case assessment. If the medical team concludes that the traveling may put your health at risk, you will be informed about it immediately after the case evaluation.

Remote Start-Up Virotherapy Package implies that your local oncologist and the one in Latvia discuss your condition and potential Rigvir® treatment by phone or via Skype. This is done to make sure all details of your health condition stay in focus.

The package costs 3,100.00 Euros. Please remember that Rigvir® vials are purchased separately.

 

In Latvia, The Oncologists Will Track How Well Your Body Responses To Rigvir® And Immediately Introduce Appropriate Changes If Needed

Before we answer your questions about how safe Rigvir® therapy is, let’s take a closer look at the venue.

If flying to Latvia isn’t an obstacle, you will be undergoing treatment at Global Virotherapy Cancer Clinic situated in Jurmala along the Baltic Coast. Everybody speaks English here, starting from the driver who meets you at the airport to the oncologist and immunologist with whom you have daily consultations.

The Rigvir® injections will be administered by a nurse after the skin test to check if you aren’t allergic to the drug. In case you are, the injection (2 mL = 0.07 oz) may be split into parts and taken together with immunosuppressant drugs.

You may wish to bring your spouse or a friend with you and that’s what cross-border patients usually do. If he/she stays in the same room with you including meals and other services, it will cost additional 100.00 EUR (roughly 120.00 USD, 88.00 GBP, 150.00 CAD, 153.00 AUD).

 
 
 

Rigvir® Therapy Causes Slight Increase Of Body Temperature Being Its Only Side Effect

We understand that you still have questions about how safe is Rigvir®. To receive your answers, fill out the form on the right so the patient coordinator will get back to you in less than 24 hours.

But if there’s one thing you should take from this article about the safety of Rigvir®, it’s that the only side effect registered so far is a slight increase in body temperature (up to 99.5°F/37.5°C) that disappears in three days.

Another patient-friendly feature of the medicine is that it is not multiplying itself outside the malignant cell. This means that Rigvir® leaves healthy tissues surrounding the tumor safe.

Watch the following stories from cancer survivors talking about their experience with Rigvir® including safety.

Jane from the USA with malignant ocular melanoma: "I chose not to do the conventional therapy in the United States."*

*Results may vary.

 

Zane from Latvia with malignant melanoma stage I: “I am very proud that after using this medication I gave birth to a healthy baby.”*

*Results may vary.

 

Success Rates Of Rigvir® Therapy In Numbers

Rigvir® isn’t a magic pill. Not even close to it.

And if we stick to dry facts, officially the drug improves the survival rates in melanoma patients only. However, real-life experience shows there’s much more to it than just treating melanoma. Here’s what you should know about the success rates of Rigvir® since 1960’s until today.

According to Acta Medica Lituanica, a medical journal (year 2002):

  • The three-year survival rate for patients with melanoma treated with surgery alone was 46-58%. Melanoma patients who received Rigvir® therapy showed a three-year survival rate of 57-84% and a five-year survival rate of 44-66%.
  • The three- and five-year survival rates for patients with ocular melanoma were 90% and 70%, respectively
  • The five-year survival rate for patients with stage III stomach cancer after surgery alone was 24-33%. Patients with the same diagnosis who completed Rigvir® treatment showed 47-60% survival rate.
  • The five-year survival rate for patients with stage II-IV rectal cancer after surgery alone was 41-68%. Patients with the same diagnosis who completed Rigvir® treatment showed 71-78%.

According to Melanoma Research, a peer-reviewed medical journal (October 2015):

According to APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica), a medical journal (July 2016):

If you or the one close to you would like to qualify for Rigvir® therapy in Latvia, please choose one of the options below. We will contact you within 24 hours but usually much sooner.

P.S. We never give empty promises. If based on your medical files you can’t benefit from using Rigvir®, the medical team will inform you immediately.